Preclinical research feasibility
In-Vivo & Preclinical Research Support — Discuss Study Feasibility
Manna Biotech can scope and coordinate eligible animal-based and preclinical research through documented external research collaboration. Each proposed study is subject to project-specific feasibility, facility availability, required ethical, regulatory and institutional approvals, and responsible personnel.
Manna Biotech does not claim to own an animal facility. Collaboration does not make every animal model or study available, grant automatic ethics or regulatory approval, or establish GLP or accreditation. No outcome or publication is guaranteed. Study acceptance requires a written scope, agreed execution responsibility, sample, data and reporting responsibilities, and mutually agreed commercial terms.
For eligible in-vivo studies, Manna Biotech coordinates with an external partner facility under an MoU. Any proposed study remains subject to the executing facility’s availability and all required ethical, regulatory and institutional approvals.
Discuss Your In-Vivo Study Requirement →Plan your project
Assess a preclinical proposal before considering execution
This page is a feasibility enquiry, not confirmation of an animal facility or an accepted study. A useful proposal states the research question, existing evidence and why an animal model is being considered. Execution responsibilities and applicable approvals must be verified separately before any commitment.
Decision 1
Review whether the question requires an animal model
Describe the evidence already available and whether an in-vitro, computational or other non-animal approach could address the next question. Where animal work is proposed, explain the model’s relevance and limitations rather than selecting it solely because a previous paper used it. Discuss alternatives with the responsible institution and specialists.
NC3Rs: rigorous research planning ↗Decision 2
Plan an interpretable study, not just a group list
Identify the primary outcome, experimental unit, comparison and basis for the proposed sample size. Consider allocation, blinding, exclusions and analysis before execution. These design questions need project-specific review; copying another study’s animal count is not a substitute for a justified design.
NC3Rs: key elements of experimental design ↗Decision 3
Verify who can execute and authorise the work
Separate planning or analysis support from animal-study execution. Before acceptance, identify the proposed facility, responsible personnel, required institutional and ethics reviews, welfare oversight and reporting route. An enquiry or collaboration discussion does not establish a signed facility relationship or approval for the proposed study.
A feasibility review should identify the unresolved conditions
Request a clear separation of the support that can be considered, the work requiring a verified executing facility and the evidence needed before proceeding. For pharma or academic preclinical proposals, keep research planning distinct from any claimed regulated-study status. A feasibility response is not an authorisation to start experiments.
What a feasibility review covers
- Written study objective, model suitability, groups, sample size and endpoints.
- Required ethical, regulatory and institutional approvals for the specific study.
- Facility availability, responsible personnel, and which work Manna may coordinate, plan or analyse versus the work the executing facility performs.
- Sample, data and reporting responsibilities; proposed molecular, biochemical, qPCR, histology or specialist work only after scope-specific feasibility review.
- Proposed anticancer, anti-obesity, antidiabetic, anti-inflammatory, immunomodulatory or analgesic endpoints and OECD 423/425 acute-toxicity methods may be discussed for feasibility; the executing facility and all required approvals must be confirmed for each study.
- Discuss proposed 28- or 90-day repeated-dose and genotoxicity studies, including OECD 474 micronucleus or OECD 475 chromosomal aberration endpoints. Device and dental material questions may include sensitization, irritation, systemic toxicity or implantation under the applicable ISO 10993 parts; ISO 10993-10 addresses sensitization and ISO 10993-23 addresses irritation. Confirm the current standard, validated method, facility scope and intended use before commissioning.
- PK/PD, bioavailability and ADME/DMPK studies, including Cmax, Tmax, AUC and half-life, are separate feasibility questions requiring an appropriate analytical method and executing facility.
- Ask about feasibility of rodent disease, oncology, immunogenicity, gut microbiome dysbiosis or colitis, phage, wound, dermal or ophthalmic models, nanoparticle biodistribution, and zebrafish or C. elegans research models. A proposed OECD 236 fish embryo acute-toxicity approach requires separate suitability and facility review. Specific species, models and endpoints are not guaranteed available.
- For authorised tissue and biofluid samples, discuss separate scRNA-seq, single-nuclei, spatial, epigenomics, metabolomics or other downstream analysis; specimen permissions, sample suitability, platform and execution site require review.
- Agreed execution responsibilities and mutually agreed commercial terms before any work begins.
Plan your enquiry
Explore feasibility, timing and a quotation
Choose the closest topic for feasibility review. These enquiry topics do not confirm that a method, facility or platform is available, and are not a confirmed service, price or completion date.
Loading choices. The website enquiry form remains available on this page.
Only enter your city and state. If provided, these are included in the prepared message; do not enter names, contact details or patient information here.
Estimated turnaround: Timing depends on the method, sample suitability, workload and reporting requirements. The team will confirm an estimate after review.
Next step: Share a non-confidential outline so the team can assess the question, requirements and next steps.
Methods, availability, fees, procurement and execution sites are confirmed for each project. In-vivo studies require applicable approvals and an authorised external partner facility under an MoU. Publication or admission is never guaranteed.
Share only a non-confidential outline initially. Do not include patient identifiers, unpublished protocols or sensitive sample details in WhatsApp. Request a suitable confidential channel before sharing them.
Select one option in each group to prepare your WhatsApp message. The website form is separate; please repeat the details there if you use it.
Feasibility enquiry
Request a feasibility review for your in-vivo study.
This enquiry is for scope review only. Do not submit patient data, confidential protocols or biological material through this form. No experiment proceeds without the appropriate permissions and a verified executing facility.